Overactive Bladder for Men with Benign Prostatic Hyperplasia
Northern California Research is conducting a phase 3 clinical research study to evaluate the safety, effectiveness, and tolerability of the study medication Vibegron in Men with Overactive Bladder (OAB) symptoms on Pharmalogical Therapy for Benign Prostatic Hyperplasia (BPH).
- Must be a male, 45 years or older
- Currently on a stable dose of a BPH treatment, and continue to remain on that treatment throughout the study.
- Having symptoms of an overactive bladder (OAB)
- PSA level <4 ng/mL
This study is 30 weeks long and includes 11 office visits. The trial doctor will review other eligibility criteria with you. All trial-related visits, tests, and medications will be provided to you at no cost. In addition, reimbursement for trial-related time and travel may be provided.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03492281